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Abstract
Background: Colorectal cancer is one of the major neoplasms and a leading cause of cancer death worldwide,
and new preventive strategies are needed to lower the burden of this disease. Metformin, a biguanide, which is
widely used for treating diabetes mellitus, has recently been suggestive to have a suppressive effect on
tumorigenesis and cancer cell growth. In a previous study conducted in non-diabetic subjects, we showed that
oral short-term low-dose metformin suppressed the development of colorectal aberrant crypt foci (ACF). ACF have
been considered as a useful surrogate biomarker of CRC, although the biological significance of these lesions
remains controversial. We devised a prospective randomized controlled trial to evaluate the chemopreventive
effect of metformin against metachronous colorectal polyps and the safety of this drug in non-diabetic post-
polypectomy patients.
Methods/Design: This study is a multi-center, double-blind, placebo-controlled, randomized controlled trial to be
conducted in non-diabetic patients with a recent history of undergoing colorectal polypectomy. All adult patients
visiting the Yokohama City University hospital or affiliated hospitals for polypectomy shall be recruited for the
study. Eligible patients will then be allocated randomly into either one of two groups: the metformin group and
the placebo group. Patients in the metformin group shall receive oral metformin at 250 mg per day, and those in
the placebo group shall receive an oral placebo tablet. At the end of 1 year of administration of metformin/
placebo, colonoscopy will be performed to evaluate the polyp formation.
Discussion: This is the first study proposed to explore the effect of metformin against colorectal polyp formation.
Metformin activates AMPK, which inhibits the mammalian target of rapamycin (mTOR) pathway. The mTOR
pathway plays an important role in the cellular protein translational machinery and cell proliferation. Patients with
type 2 diabetes taking under treatment with metformin have been reported to be at a lower risk of cancer
development than those not taking under treatment with metformin. We showed in a previous study that
metformin suppressed the formation of human colorectal ACF. We therefore decided to conduct a study to
determine whether metformin might suppress the formation of human colorectal polyps.
Trial registration: This trial has been registered in the University hospital Medical Information Network (UMIN)
Clinical Trials Registry as UMIN000006254
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Colorectal cancer (CRC) is a major neoplasm worldwide
[1], and both its prevalence and mortality have been
increasing [2]. Removal of colorectal polyps has been to
shown to reduce the risk of future development of col-
orectal cancer and advanced adenoma [3,4]. On the
other hand, patients with polyps (adenomas and/or
hyperplastic polyps) constitute a high-risk group for the
development of metachronous colorectal polyps and/or
CRC [5]. Therefore, a paradigm shift from surveillance
for early detection of cancer or adenomas (polypectomy)
to new strategies for prevention, including chemopre-
vention, is needed to lower the burden of this disease.
Several large epidemiologic and/or clinical studies have
evaluated the possible preventive effects of more than
200 agents, including fiber, calcium, and non-steroidal
anti-inflammatory drugs (NSAIDs), including aspirin
and selective cyclooxygenase-2 (COX-2) inhibitors, in
protecting against CRC development [6]. NSAIDs, espe-
cially COX-2 inhibitors, administered either alone or in
combination with other agents, have shown the most
promise, until date, for CRC risk reduction [4], although
reports have revealed an increased risk of serious cardio-
vascular events associated with the use of COX-2 inhibi-
tors [7,8]. In light of the adverse cardiovascular effects
of COX-2 inhibitors and lack of demonstrable efficacy
of the other agents that had initially shown promise in
this setting, novel drugs that would be both safe and
effective for CRC prevention need to be developed. CRC
is associated with lifestyle-related diseases, such as dia-
betes mellitus and obesity [9-12], therefore, we consid-
ered that these conditions might represent potential
new targets for CRC chemoprevention.
Metformin (1,1-dimethylbiguanide hydrochloride) is a
biguanide derivative that has long been used widely for
treating diabetes mellitus [13]. It decreases basal glucose
output by suppressing gluconeogenesis and glycogenolysis
in the liver and increasing glucose uptake by the muscle.
Because metformin does not directly stimulate insulin
secretion, it is associated with a lower risk of hypoglycemia
than other oral antidiabetic drugs [14]. The molecular
mechanism involved in the action of metformin is liver
kinase B-1dependent activation of AMP-activated protein
kinase (AMPK) [15]. Patients with type 2 diabetes under
treatment with metformin have been reported to be at a
lower risk of cancer development (including CRC) than
those not under treatment with metformin [16,17]. This
evidence suggests that metformin might be a candidate
agent for CRC chemoprevention in diabetic patients.
However, since diabetes mellitus itself is a risk factor for
cancer, treatment of diabetes mellitus may reduce the risk;
therefore, it is still unclear whether the suppressive effect
of metformin against CRC may be exerted by the direct
chemopreventive effect of the drug or be mediated by its
antidiabetic effect. Therefore, we considered that in order
to validate the chemopreventive effect of metformin, a
clinical trial in nondiabetic patients needs to be conducted.
In previous studies, we demonstrated the chemopre-
ventive effect of metformin in two rodent models (a
genetic model and a chemically-induced cancer model)
and one human study of colorectal carcinogenesis. We
showed that metformin suppressed the development of
intestinal polyps in adenomatous polyposis coli (APC-
Min/+) mise, a murine model of familial adenomatous
polyposis [18]; furthermore, we showed that metformin
suppressed azoxymethane-induced formation of colorec-
tal aberrant crypt foci (ACF) by activating AMPK [19].
Both studies were performed in nondiabetic mice, which
suggested the direct chemopreventive potential of met-
formin per se. In the study conducted on nondiabetic
human subjects, we showed that oral low-dose adminis-
tration of metformin (250 mg per day) suppressed the
formation of colorectal ACF and that the drug was safe
[20]. ACF are considered as a reliable surrogate biomar-
ker of CRC [21], although their biological significance
still remains controversial. Therefore, in CRC chemopre-
vention trials, in general, the incidence of polyps or of
the cancer itself is set as the study endpoint. Although
the incidence rate of CRC would be the most reliable
endpoint, use of this endpoint would be unsuitable for
chemoprevention trials, because of the relatively low
occurrence rate of CRC in the general population [22]
and the long-term observation period that it would
necessitate. Moreover, observation of polyps detected in
annual colonoscopies until they grow into cancer would
be fraught with ethical problems. Thus, we set the
appearance of colorectal polyps as a suitable endpoint
for our chemopreventive trial.
Thus, we devised a prospective randomized controlled
trial to evaluate the chemopreventive effect of metfor-
min against the development of metachronous colorectal
polyps and the safety of this drug in nondiabetic post-
polypectomy patients.
This is the first clinical trial of metformin as a chemo-
preventive agent against metachronous colorectal polyps
in humans.
Methods/Design
Study design and setting
This study is designed as a multi-center, double-blind,
placebo-control, randomized controlled trial to be per-
formed in nondiabetic patients with a recent history of
undergoing colorectal polypectomy. The study will take
place at the Division of Gastroenterology, Yokohama
City University Hospital, and its 5 affiliate hospitals. The
coordinating office shall be at Yokohama City University
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and data collection to be conducted at this site.
Ethical considerations and registration
The study protocol is in compliance with the Declaration
of Helsinki [23] and the Ethics Guidelines for Clinical
Research published by the Ministry of Health, Labour,
and Welfare, Japan [24]. We obtained approval for this
study from the Ethics committee of Yokohama City Uni-
versity Hospital on July 8
th 2011. The protocol and
informed consent forms were approved by the institu-
tional ethics committee at each of the participating insti-
tutions. This trial has been registered in the University
hospital Medical Information Network (UMIN) Clinical
Trials Registry as UMIN000006254. Written informed
consent for participation in the study will be obtained
from all the participating patients. The trial results will
be reported in conformity with the Consolidated Stan-
dards of Reporting Trials (CONSORT) 2010 guidelines
[25].
Eligibility criteria
All adult patients visiting the hospital for polypectomy
will be recruited for the study.
The inclusion criteria are as follows:
1) No colorectal polyps present after the polypectomy
2 )A g e4 0t o8 0y e a r sa so nt h ed a t eo fi n f o r m e d
consent
3) Willingness to provide written informed consent
The likelihood of development of colorectal polyps in
the young is low and the diagnosis history of polyps in the
young is usually related to familial adenomatous polyposis
or hereditary non-polyposis colorectal cancer; on the
other hand, the elderly have various complications. This
was the rationale for our setting the age criterion for inclu-
sion in this study as 40 to 80 years.
The exclusion criteria are as follows:
1) History of diabetes mellitus (use of medication and/
or HbA1c over 6.5%)
2) History of regular use (defined as at least once per
week) of NSAIDs and/or aspirin
3) History of bowel surgery
4) History of malignant disease (excluding carcinoma
in adenoma, carcinoma in situ that has already been
resected)
5) History of heart failure, renal failure, liver cirrhosis
or chronic hepatic failure
6) History of familial adenomatous polyposis
7) History of hereditary non-polyposis colorectal
cancer
8) History of inflammatory bowel disease
9) Pregnancy or possibility of pregnancy
10) Patients judged as inappropriate candidates for the
trial by the investigators
Intervention
All eligible patients will be allocated randomly to one of
two groups, the metformin group and the placebo group.
Endoscopists, doctors at the follow-up outpatient clinics
and patients will be blinded to the allocation. Patients in
the metformin group shall receive oral metformin at
250 mg per day, and those in the placebo group shall
receive oral placebo tablet. At the end of 1 year of admin-
istration of metformin/placebo, colonoscopy will be per-
formed to evaluate the polyp formation.
Outcome measurements
The primary endpoint shall be the prevalence of colorec-
tal polyps and number of polyps after 1-year’s interven-
tion. The endoscopic examinations and polypectomies
will be performed using Olympus colonoscopes (model
H260AZI). The day before the endoscopy, each patient
will be instructed to consume a low-residue diet and
shall receive 5 mg of oral sodium picosulfate. On the day
of the endoscopy, the patients shall receive 2000 ml of
polyethylene glycol (PEG). If the feces are not sufficiently
clear, an additional 1000 - 2000 ml of PEG may be given
to ensure sufficient bowel cleaning. At the time of the
polypectomies, the endoscope shall be inserted into the
cecum, and the entire colorectum will be carefully
observed as the endoscope is pulled back. If any polyps
are detected, polypectomy will be performed. At the end
of 1 year of administration of metformin/placebo, the
same endoscopists will perform the repeat endoscopic
examinations. If a polyp(s) is detected at the repeat colo-
noscopy (after treatment for one year), a biopsy will be
performed. A total of 6 endoscopists from Yokohama
City University Hospital and the 5 affiliate hospitals will
perform the polypectomies and endoscopic examinations.
All procedures will be recorded on DVD, and all the
polyps will be photographed. The number of polyps in
each patient will first be counted by the operators during
the performance of the colonoscopy. To further ensure
validity, the number of polyps will be counted again
through observation of the recorded DVD by 3 blinded
expert endoscopists (H.T, H.E, and E.S). If these expert
endoscopists judge the colonoscopic examination as hav-
ing been inadequate in any case, that case will be
excluded. The biopsied polyps will be evaluated by expert
pathologists (Y.N and S.Y).
The secondary outcomes are (1) the drug safety; adverse
events will be monitored by the doctor at every follow-up
visit to the outpatient clinic. Adverse events will be graded
according to the National Cancer Institute Common Toxi-
city Criteria for Adverse Events (NCI-CTCAE), version
4.0. Diarrhea, the most frequent adverse event related to
use of metformin, will be watched for spontaneous resolu-
tion within a few days and/or managed by antiflatulent
drugs. If Grade 3 or more severe adverse events appear,
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nating office and the case will be withdrawn from the
study at that point; (2) laboratory data (fasting blood glu-
cose, fasting blood insulin, HbA1c, total cholesterol, LDL-
cholesterol, blood urea nitrogen (BUN), creatinine); (3) the
number of ACF. At the time of the 1-year colonoscopy
and polypectomy, the lower rectal region from the middle
Houston valve to the dentate line will be washed thor-
oughly with water, sprayed with 0.25% methylene blue,
which would be left to stand for 2 min, then again washed
thoroughly with water. The number of rectal ACF will be
counted with a magnifying endoscope [21]; (4) physical
examination findings (body weight, body mass index
(BMI)). Metformin is widely used as an antidiabetic drug
that improves insulin resistance. The effect of metformin
on insulin resistance and the plasma lipid profile will be
evaluated by comparing these parameters measured at the
baseline and at 1 year in the metformin group and placebo
group. All participants will receive physical examination
and laboratory tests at the time of the 1-year endoscopic
examination and polypectomy; (5) effects of metformin on
the cell-proliferative and apoptotic activities in the rectal
epithelium and polyps (if any). Colonic epithelial samples
will be obtained from the same trial patients by biopsy at
the time of the 1-year colonoscopy and polypectomy. The
cell-proliferative activity will be evaluated by staining for
the proliferative cell nuclear antigen (PCNA), and the cell-
apoptotic activity by the terminal deoxynucleotidyl trans-
ferase-mediated dUTP-biotin nick end labeling (TUNEL)
method; (6) expression levels of protein (AMPK, mTOR/
S6K) in the rectal epithelium and polyps (if any) that are
thought to be pharmacological targets of metformin. The
expression levels of these proteins shall be determined by
western blot analysis.
Randomization
The investigator shall convey the patient’s details to the
central registration centre via fax. After an eligibility
check, the patients will be randomly assigned to receive
metformin or placebo at the central registration centre by
a computer program, using a minimization method, with
stratification by institute, age, gender and BMI. In this
way, the patient assignment will be concealed from the
investigator. The randomization center will allocate a
numbered treatment pack to each patient, which will con-
tain all the drugs or placebos needed to complete a course
of the trial treatment for one patient.
Drug supply
Metformin will be purchased from Dainippon Sumitomo
Parma Co., Ltd. The placebo (250 mg lactose) will be
purchased from Kokando Co., Ltd, Toyama, Japan. All
trial drugs will be packaged identically and identified
only by number. Subjects will be instructed to take one
tablet of the trial drug after breakfast every day, and to
visit the hospital every 4 weeks for evaluation of the sub-
jective symptoms and for receiving a new supply of medi-
cation. Compliance will be monitored by counting the
empty drug packages returned by the patients at every
visit to the outpatient clinic.
Sample size estimation
We previously showed that metformin administered at
250 mg/d for 1 month directly suppressed the formation
of ACF. In that study, mean number of ACF per patient
decreased significantly from 8.78 ± 6.45 (baseline) to
5.11 ± 4.99 (at 1 month, p=0 . 0 0 7 ) [20]. Based on a similar
study, Takayama et al. reported that sulindac administra-
tion at 300 mg/d for 2 months to post-polypectomy
patients suppressed ACF formation, decreasing the num-
ber of ACF from 7.70 ± 4.04 (baseline) to 4.00 ± 2.95 (at
2m o n t h s ,p < 0.001) [26]. From these reports, we esti-
mated that metformin and sulindac may have equivalent
effect on suppression of ACF formation. Moreover, from
the same study, Takayama et al. reported that in the post-
polypectmoy patients who received 2-months’ interven-
tion, the number of polyps (hyperplastic polyp and
adenoma) at 1 year after the treatment was significantly
lower in the sulindac group in comparison with that in the
placebo group (26/48 (54.2%) vs. 15/48 (31.3%), p = 0.025)
[26]. Therefore, we speculated that 1-year’s treatment with
metformin might yield equivalent suppression of meta-
chronous polyp formation to that with sulindac. To detect
the reduction in the number of metachronous polyps in
the metformin group using the chi-square test with a two-
sided significance level of 5% and a power of 80%, it was
found that a sample size of 68 patients per group would
be necessary. Assuming a 10% dropout rate, we propose
to recruit 75 patients per group, that is, a total of 150
patients.
Statistical analysis
T h ep r e v a l e n c eo fp o l y p si ne a c hg r o u p ,t h ep r i m a r y
endpoint, will be compared between the metformin
group and placebo group by the chi-square test. The
safety, one of the secondary endpoints, will be similarly
compared by the chi-square test. The remaining results
in the two groups will be compared by the Mann-Whit-
ney U test or Student’s t test. A P value of < 0.05 shall
be regarded as indicative of significance. The analysis
will be performed using SPSS, version 17.0 (SPSS Inc.,
Chicago, Il.).
Trial steering committee and data monitoring committee
The Trial Steering Committee and Data Monitoring
Committee shall be located at the Department of Clinical
Research, Yokohama City University School of Medicine.
The committee shall consist of three people: Yutaka
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Yamaguchi, Ph.D. The Management Team will monitor
the trial progress status and data by face-to-face and/or
telephonic contact with each of the six sites every month.
Study flow
A flow chart of the study is shown in Figure 1.
Discussion
This is the first study proposed to explore the effect of
metformin against colorectal polyp formation. Metformin
activates AMPK, which inhibits the mammalian target of
rapamycin (mTOR) pathway [15]. The mTOR pathway
plays an important role in the cellular protein translational
machinery and cell proliferation [27]. The best-character-
ized downstream effector of mTOR is S6 kinase, which
regulates the initiation and elongation phases of transla-
tion [28]. Activation of the mTOR pathway has been
shown to accelerate cell cycle progression from G1 to S in
CRC DLD-1 cells [29]. Therefore, AMPK activation may
inhibit cell growth and proliferation by suppressing pro-
tein synthesis, thereby having a potent antiproliferative
effect. Recent evidence indicates that metformin has a
suppressive effect on tumorigenesis and cancer cell growth
[30-32]. In one study, metformin was demonstrated to
activate AMPK and consequently decrease cellular prolif-
erative activity, to produce a general decrease in protein
synthesis in vitro in human breast carcinoma cells [30].
Metformin was also shown to inhibit the proliferation of
human prostate cancer cells [32].
This trial may have the following limitations. First, we
do not propose to conduct a dose-response study of the
effect of metformin on colorectal polyp formation. Until
now, trails of metformin for cancer prevention and adju-
vant treatment have been conducted using high-dose met-
formin (500 - 2000 mg per day). However, high-dose
metformin use is associated with the risk of development
of lactic acidosis and gastrointestinal adverse effects
(including diarrhea). Gontier et al. reported from a PET/
CT study, that subjects treated with antidiabetic agents,
including metformin, showed high and diffuse bowel
uptake of 18 F-FDG [33]. This suggests that AMPK is pre-
sent in abundance in the bowel epithelium and that activa-
tion of AMPK by metformin up-regulates the expression
of glucose transporters. We showed in a previous study
that oral low-dose metformin (250 mg per day) suppressed
Figure 1 Study Flow.
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leading us to surmise that oral low-dose metformin may
also be effective for CRC chemoprevention. Therefore, we
planned to conduct this trial with low-dose metformin.
Second, repeat colonoscopy at 1 year may be too short to
allow reliable detection of differences between the groups.
However, this is first chemoprevention study of metformin
for CRC, long-term administration of placebo to post-
polypectomy patients may entail ethical problems. There-
fore, this time we planned repeat colonoscopy at 1 year. In
order to detect the effect of metformin with less effort, we
elected to select participants who had undergone polypect-
omy for this trial, because these patients constitute a high-
risk group for the development of metachronous colorec-
tal polyps and/or CRC [5]. And after safety of chronic
metformin administration for non-diabetic patients is con-
firmed, we would like to follow up the participants of this
trial, and conduct long-term chemoprevention trial for
CRC.
If metformin were found to be effective for the pre-
vention of CRC, the impact would be extremely large.
We consider it of interest, therefore, to determine
whether metformin might suppress the formation of
human colorectal polyps.
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